. Author manuscript; available in PMC: 2022 Mar 1.

Published in final edited form as: Leukemia. 2021 Mar 2;35(9):2539–2551. doi: 10.1038/s41375-021-01179-4

Table 3:

Comparison of pretreatment characteristics of patients who began maintenance therapy and those who did not

	205 patients who began maintenance therapy	512 patients who did not receive maintenance therapy	p-value^*
Age in years, median (range)	49 (19–60)	47 (18–61)	0.08¹
Female, N (%)	103 (50%)	295 (58%)	0.07²
FLT3 mutation, N (%)			0.0016²
TKD (No ITD)	59 (29%)	103 (20%)
ITD (ratio <0.7	103 (50%)	238 (47%)
ITD (ratio ≥0.7)	43 (21%)	171 (33%)
ELN 2017, N (%)			<0.01²
Favorable	80 (57%)	117 (39%)
Intermediate	33 (24%)	90 (30%)
Adverse	25 (18%)	96 (32%)
Pre-treatment WBC,	32.0 (0.6–421.8)	35.8 (0.8–329.8)	0.44¹
x10³/ul, median (range)

p-values

^1:

Kruskal Wallis

^2:

Chi square